AstraZeneca (LSE:AZN) moved into focus after announcing an AI and cloud partnership with Oracle aimed at speeding clinical research, alongside fresh oncology and rare disease trial updates across multiple late stage programs. Recent announcements around the Oracle AI partnership, new oncology data for presentation at ESMO 2026, and fresh rare disease readouts arrive while AstraZeneca's share price has slipped around 8.8% year to date, even as the 5-year total shareholder return of 53.9% points to stronger long-run momentum. Scan AstraZeneca's AI driven drug development story against a curated pool of peers by reviewing the 39 profitable AI stocks that aren't just burning cash that are already turning advanced tech into real earnings.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.